期刊文献+

血液系统疾病相关肺高血压的流行病学与发病机制 被引量:2

Epidemiology and pathogenesis of pulmonary hypertension associated with haematological diseases
下载PDF
导出
摘要 肺高血压指肺内循环系统发生高血压。伴或不伴有肺小动脉病变为特征的恶性肺血管疾病,往往引起右心衰竭甚至死亡,肺动脉高压与血液病关系密切,但目前未被血液科医生及时识别。本研究总结了可能会引起肺高血压的血液系统疾病,如溶血性贫血、骨髓增殖性疾病、浆细胞疾病,相关肺动脉高压的治疗,阐述可能的发病机制及临床表现,旨在提高血液科医师对肺高血压的认识。 Pulmonary hypertension(PH)refers to high blood pressure within the pulmonary circulation,which is a kind of malignant pulmonary vascular disease with or without small pulmonary artery lesions,often causes right heart failure and even death.PH is closely related to a blood disease,but is not recognized in time by a hematologist.Reviewed in this study were blood diseases that might cause PH,such as hemolytic anemia,myeloproliferative diseases,plasma cell disease and treatment-related PH.Possible pathogenesis was also described,aiming at improving the hematologist’s understanding of PH.
作者 冯友繁 张启科 曹云山 魏小芳 彭文辉 Feng You-fan;Zhang Qi-ke;Cao Yun-shan;Wei Xiao-fang;Peng Wen-hui(Department of Hematology,Gansu Provincial Hospital,Lanzhou 730000,China;Department of Cardiology,Gansu Provincial Hospital,Lanzhou 730000,China;Department of Cardiology,Affiliated No.10 People's Hospital of Tongji University,Shanghai 200072,China)
出处 《兰州大学学报(医学版)》 CAS 2018年第5期16-20,共5页 Journal of Lanzhou University(Medical Sciences)
基金 国家自然科学基金项目(81670230).
关键词 肺高血压 溶血性贫血 骨髓增殖性疾病 达沙替尼 脾切除 骨髓移植 pulmonary hypertension hemolytic anemia myeloproliferative diseases dasatinib splenectomy bone marrow transplantation
  • 相关文献

参考文献5

二级参考文献57

  • 1荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:117
  • 2Fullmer A, Kantarjian H, Cortes J, et al. Dasatinib for the treat- ment of chronic myeloid leukemia IJl. Expert Rev Hematol, 2011, 4(3):253-260.
  • 3NCCN clinical practice guidelines in oncology:chronic myeloge- nous leukemia [ S/OL ] .Version 2, 2013. http://www.nccn.org/pro- fessionals/physician-gls/f-guidelines.asp#cml.
  • 4Montani D, Seferian A, Savale L, et al. Drug-induced pulmonary arterial hypertension: a recent outbreak [J]. Eur Respir Rev, 2013, 22(29): 244-250.
  • 5Montani D, Bergot E, Giinther S, et al. Pulmonary arterial hyper- tension in patients treated by dasatinib [J]. Circulation, 2012, 125( 17):2128-2137.
  • 6Rasheed W, Flaim B, Seymour JF, et al. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia[J]. Leuk Res, 2009, 33(6): 861-864.
  • 7Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and fight ventricle failure in a previously allografted CML patient [J]. Bone Marrow Trans- plant, 2009, 43( 12): 967-968.
  • 8Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmo- nary hypertension?[ J]. BMC Pulm Med, 2011, 11:30.
  • 9Dumitreseu D, Seek C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treat- ment for chronic myeloid leukaemia[J]. Eur Respir J, 2011, 38 ( 1 ):218-220.
  • 10Orlandi EM, Rocca B, Pazzano AS, et al. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasat- inib treatment for chronic myeloid leukaemia [J]. Leuk Res, 2012, 36( 1 ): e4-e6.

共引文献36

同被引文献25

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部